Sorin rejects analysts' forecast of divestment
This article was originally published in Clinica
Sorin has dismissed speculation that it may divest its renal care business. Analysts at Morgan Stanley Dean Witter distributed a report on the Italian biomedical company last month which said: "Although [the renal care business] is profitable and generates cash, we believe, based on the company's stated strategy, that Sorin would entertain exiting the business if the right opportunity, for example an attractive cardiovascular surgery business, came along."
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.